Cargando…

Glucagon‐like peptide‐1 receptor expression in the human eye

Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hebsgaard, Josephine B., Pyke, Charles, Yildirim, Emre, Knudsen, Lotte B., Heegaard, Steffen, Kvist, Peter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099507/ https://www.ncbi.nlm.nih.gov/pubmed/29707863 http://dx.doi.org/10.1111/dom.13339

Ejemplares similares

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Long‐acting glucagon‐like peptide‐1 receptor agonists have direct access to and effects on pro‐opiomelanocortin/cocaine‐ and amphetamine‐stimulated transcript neurons in the mouse hypothalamus
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2016)

Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
por: Farkas, Erzsébet, et al.
Publicado: (2020)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation
por: Thangavelu, Thiyagarajan, et al.
Publicado: (2020)

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease
por: Hansen, Henrik H., et al.
Publicado: (2016)

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2022)

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
por: Nørgaard, Caroline Holm, et al.
Publicado: (2022)

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
por: Arora, Tulika, et al.
Publicado: (2016)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
por: Lucey, Maria, et al.
Publicado: (2020)

Genetic Evidence for Repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) Agonists to Prevent Heart Failure
por: Daghlas, Iyas, et al.
Publicado: (2021)

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
por: Vesterinen, Tiina, et al.
Publicado: (2023)

Equine glucagon-like peptide-1 receptor physiology
por: Kheder, Murad H., et al.
Publicado: (2018)

The putative signal peptide of glucagon-like peptide-1 receptor is not required for receptor synthesis but promotes receptor expression
por: Ge, Yunjun, et al.
Publicado: (2014)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
por: Willard, Francis S., et al.
Publicado: (2012)

Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
por: Rode, Anna K. O., et al.
Publicado: (2022)

Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons
por: Zeng, Ningxiang, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
por: Kang, Mi Yeon, et al.
Publicado: (2015)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
por: Hennen, Stephanie, et al.
Publicado: (2016)

Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
por: Bueno, Ana B., et al.
Publicado: (2016)

Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
por: Willard, Francis S., et al.
Publicado: (2012)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
por: Lin, Hua V., et al.
Publicado: (2018)

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
por: Cork, Simon C., et al.
Publicado: (2015)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake
por: Singh, Ishnoor, et al.
Publicado: (2022)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists
por: Urva, Shweta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_90152l7ktdmtoq0m4pbnve5iuk